ストックスクリーナーアプリを入手
890.05
2.34%
20.33
アフターアワーズ：
889.25
-0.80
-0.09%
前日終値:
$869.72
開ける：
$875.27
24時間の取引高:
656.50K
Relative Volume:
1.02
時価総額：
$55.97B
収益：
$4.16B
当期純損益:
$1.29B
株価収益率:
45.45
EPS:
19.5837
ネットキャッシュフロー:
$734.26M
1週間 パフォーマンス:
+8.77%
1か月 パフォーマンス:
-9.93%
6か月 パフォーマンス:
+10.51%
1年 パフォーマンス:
+6.62%
1日の値動き範囲:
$873.23
$892.85
1週間の範囲:
$813.05
$892.85
52週間の値動き範囲:
$661.85
$1,072.75
Argen X Se Adr Stock (ARGX) Company Profile
Compare ARGX vs VRTX, MRNA, REGN, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
890.05 | 55.97B | 4.16B | 1.29B | 734.26M | 19.58 |
VRTX
Vertex Pharmaceuticals Inc
|
524.52 | 132.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
245.81 | 98.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
805.67 | 82.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ONC
Beone Medicines Ltd Adr
|
386.46 | 43.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-08-26 | アップグレード | UBS | Neutral → Buy |
| 2026-08-24 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2026-08-04 | 再開されました | Guggenheim | Buy |
| 2026-03-10 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-12-18 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2025-11-24 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-09-15 | 再開されました | Truist | Buy |
| 2025-09-11 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-08-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-07-08 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-07-03 | 再開されました | Morgan Stanley | Overweight |
| 2025-05-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | アップグレード | Deutsche Bank | Sell → Hold |
| 2025-01-17 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-11-12 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | アップグレード | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | 再開されました | Raymond James | Strong Buy |
| 2024-10-04 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-08-06 | アップグレード | Barclays | Equal Weight → Overweight |
| 2024-07-25 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-07-23 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-20 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-12-20 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | 開始されました | Scotiabank | Sector Perform |
| 2023-07-24 | ダウングレード | UBS | Buy → Neutral |
| 2023-07-17 | 再開されました | Evercore ISI | Outperform |
| 2023-06-15 | 開始されました | Societe Generale | Sell |
| 2023-05-31 | 開始されました | UBS | Buy |
| 2023-04-25 | 開始されました | Citigroup | Buy |
| 2023-03-14 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | 開始されました | William Blair | Outperform |
| 2022-10-12 | 開始されました | Oppenheimer | Perform |
| 2022-07-29 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | 再開されました | Stifel | Buy |
| 2022-05-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-11-29 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-28 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-09-23 | アップグレード | Redburn | Neutral → Buy |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | 開始されました | Deutsche Bank | Hold |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-06-18 | 開始されました | UBS | Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-05-10 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | 開始されました | Redburn | Neutral |
| 2021-03-05 | 繰り返されました | H.C. Wainwright | Neutral |
| 2021-02-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-08-19 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2020-07-29 | 開始されました | H.C. Wainwright | Neutral |
| 2020-02-10 | 開始されました | BofA/Merrill | Buy |
| 2019-11-05 | 開始されました | Credit Suisse | Neutral |
| 2019-10-31 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | 開始されました | JP Morgan | Overweight |
| 2019-09-27 | 開始されました | Wells Fargo | Market Perform |
| 2019-09-16 | 再開されました | Cowen | Outperform |
| 2019-06-28 | 開始されました | Robert W. Baird | Outperform |
| 2019-01-18 | 再開されました | SunTrust | Buy |
| 2019-01-04 | 開始されました | Morgan Stanley | Overweight |
| 2018-12-17 | 開始されました | Goldman | Buy |
| 2018-12-14 | 開始されました | Wolfe Research | Outperform |
| 2018-06-29 | 開始されました | Nomura | Buy |
| 2018-04-09 | 開始されました | SunTrust | Buy |
| 2018-01-29 | 繰り返されました | JMP Securities | Mkt Outperform |
すべてを表示
Argen X Se Adr (ARGX) 最新ニュース
argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026 - GlobeNewswire Inc.
Zacks Investment Ideas feature highlights: Cummins, Argenx and PACCAR - Zacks Investment Research
Best 3 Non-AI Stocks to Buy Now on the Dip Amid the AI Stock Selloff - Zacks Investment Research
Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Zacks Investment Research
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026 - GlobeNewswire Inc.
argenx Meets Primary Endpoint in Phase II Celiac Disease Study - Zacks Investment Research
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe - Zacks Investment Research
argenx reports Phase 2 FB102 celiac trial met primary endpoint - Mugglehead Investment Magazine
HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX - Zacks Investment Research
10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now? - The Motley Fool
argenx SE (1AE.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
argenx SE (ARGX.BR) Stock Price, News, Quote & History - Yahoo! Finance Canada
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline - GlobeNewswire Inc.
SGIOY Stock Price, Quote & News - Syfe
argenx at wells fargo healthcare conference: broadening beyond vyvgart By Investing.com - Investing.com India
argenx at wells fargo healthcare conference: broadening beyond vyvgart - investing.com
Argenx Se Stock Price Forecast. Should You Buy ARGX? - StockInvest.us
argenx SEADR Key Financial Ratios – Valuation, Profitability & More - Value Research
argenx to Present at Upcoming Investor Conferences - Barchart.com
BNTX Stock Price, Quote & News - Syfe
argenx (ARGX) Falters: Slides 3.37% as Bulls Defend Key $972 SupportSocial Sentiment - siam.in
argenx (ARGX) Falters: Slides 3.37% as Bulls Defend Key $972 SupportBlue Chip Entry Points - dars.gov.et
argenx SEADR Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Resilient Argenx stock holds near record highs after Forte Biosciences acquisition - ad-hoc-news.de
Resilient Argenx stock touches fresh all-time high after Forte Biosciences deal - ad-hoc-news.de
Argenx stock hits all-time high at 1059.86 USD By Investing.com - Investing.com South Africa
argenx Completes Acquisition of Forte Biosciences, Inc. - Barchart.com
Forte Biosciences Director David W. Gryska Sells Entire Stake Amid Merger with argenx BV - Kalkine Media
Argenx Completes Acquisition of Forte Biosciences - marketscreener.com
Why is Argen-X stock climbing today? By Investing.com - Investing.com UK
UBS upgrades argenx stock rating on Vyvgart sales outlook By Investing.com - Investing.com India
Why is Argen-X stock climbing today? - investing.com
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX) - theglobeandmail.com
Argenx keeps climbing, shrugging off Deutsche Bank's reservations - marketscreener.com
Deutsche Bank Downgrades Argenx to Hold, Lifts PT - www.marketscreener.com
Deutsche Bank downgrades argenx stock to Hold on valuation By Investing.com - Investing.com Nigeria
Deutsche Bank downgrades argenx stock to Hold on valuation By Investing.com - Investing.com Australia
Deutsche Bank downgrades argenx stock to Hold on valuation - Investing.com
ETFs Investing in argenx SE Sponsored ADR Stocks - TradingView
Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)? - Yahoo Finance
Resilient Argenx stock climbs after positive myositis data and fresh analyst targets - Ad-hoc-news.de
RBC Capital raises argenx stock price target on myositis data - Investing.com
Strong Argenx stock extends rally after Vyvgart trial win and analyst target hikes. - Ad-hoc-news.de
Gold Gains 1%; NY Empire State Manufacturing Index Rises In August - Sahm
Citizens raises argenx stock price target to $1,200 on trial results - Investing.com
argenx (ARGX) Latest Price Review: Adds 0.52% to Close at $992.99; Key Levels: the Supplied Trading Band Runs From $943.34 to $1,042.64 for the Current SessionMerger Arbitrage - dars.gov.et
Argenx's Positive Vyvgart Data in Autoimmune Indication Supports Growth and FB102 Broadens Portfolio - Morningstar
Resilient Argenx stock jumps after positive Vyvgart Phase 3 data - Ad-hoc-news.de
TD Cowen raises argenx stock price target to $1,353 on myositis outlook - Investing.com Australia
TD Cowen raises argenx stock price target to $1,353 on myositis outlook - Investing.com
Argen X Se Adr (ARGX) 財務データ
収益
当期純利益
現金流量
EPS
0.51%
1.15%
大文字化:
|
ボリューム (24 時間):